Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

What Happened: The latest Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission uncovered CAGNONI, ...

Merit Financial Group LLC bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the 4th quarter, ...

William Blair lowered their Q4 2024 earnings per share estimates for Incyte in a research note issued on Tuesday, January ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

根据 InvestingPro 分析，市值140亿美元的生物制药公司Incyte Corp (NASDAQ: INCY )财务状况良好。该公司执行副总裁兼首席医疗官Steven H. Stein最近报告了一笔重大股票交易。根据最近的SEC文件，Stein于2025年1月21日出售了12,352股Incyte普通股。这些股票以每股72.69美元的价格售出，总交易价值约为897,866美元。此次出售后 ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has ...

US FDA approves Incyte and Syndax’s Niktimvo 9 mg & 22 mg vial sizes to treat chronic graft-versus-host disease: Wilmington, Delaware Friday, January 17, 2025, 13:30 Hrs [IST] I ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.